iTeos Therapeutics’ (ITOS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of iTeos Therapeutics (NASDAQ:ITOSFree Report) in a research report released on Friday,Benzinga reports. They currently have a $46.00 price objective on the stock.

ITOS has been the topic of a number of other reports. Wedbush reiterated an “outperform” rating and set a $25.00 price objective on shares of iTeos Therapeutics in a research note on Tuesday, November 12th. Wells Fargo & Company assumed coverage on shares of iTeos Therapeutics in a report on Tuesday, August 13th. They issued an “overweight” rating and a $31.00 price target on the stock. Finally, JPMorgan Chase & Co. decreased their target price on shares of iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating on the stock in a report on Monday, August 12th.

Check Out Our Latest Research Report on iTeos Therapeutics

iTeos Therapeutics Stock Down 2.7 %

Shares of NASDAQ:ITOS opened at $8.23 on Friday. The company has a 50-day moving average price of $10.27 and a two-hundred day moving average price of $14.01. iTeos Therapeutics has a twelve month low of $7.99 and a twelve month high of $18.75. The firm has a market capitalization of $300.64 million, a PE ratio of -2.61 and a beta of 1.39.

iTeos Therapeutics (NASDAQ:ITOSGet Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.18) by $0.13. Analysts anticipate that iTeos Therapeutics will post -3.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On iTeos Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ITOS. Geode Capital Management LLC grew its holdings in shares of iTeos Therapeutics by 3.2% during the third quarter. Geode Capital Management LLC now owns 640,350 shares of the company’s stock worth $6,540,000 after purchasing an additional 20,092 shares in the last quarter. XTX Topco Ltd purchased a new position in iTeos Therapeutics in the 3rd quarter worth approximately $186,000. Wellington Management Group LLP grew its stake in iTeos Therapeutics by 20.9% in the 3rd quarter. Wellington Management Group LLP now owns 105,769 shares of the company’s stock worth $1,080,000 after buying an additional 18,255 shares in the last quarter. State Street Corp raised its position in shares of iTeos Therapeutics by 21.9% during the 3rd quarter. State Street Corp now owns 1,175,353 shares of the company’s stock valued at $12,000,000 after buying an additional 211,452 shares in the last quarter. Finally, Readystate Asset Management LP lifted its holdings in shares of iTeos Therapeutics by 97.2% during the 3rd quarter. Readystate Asset Management LP now owns 169,819 shares of the company’s stock worth $1,734,000 after acquiring an additional 83,700 shares during the last quarter. 97.16% of the stock is currently owned by institutional investors.

About iTeos Therapeutics

(Get Free Report)

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

Featured Articles

Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.